LDLR and familial hypercholesterolemia: Of particular interest is the observation that the inhibition of ANGPTL3 significantly reduced LDL-C in patients with homozygous familial hypercholesterolemia (HoFH), a genetic disease characterized by the mutation of both alleles of hepatic LDL receptor gene responsible for LDL internalization and degradation [46].